The “Trojan Horse” Approach to Tumor Immunotherapy: Targeting the Tumor Microenvironment

ERK-Dependent Bim Modulation Downstream of the 4-1BB-TRAF1 Signaling Axis Is a Critical Mediator of CD8 T Cell Survival In Vivo

(2014) L. Sabbagh et al.   JOURNAL OF IMMUNOLOGY

Activation of NF- B1 by OX40 Contributes to Antigen-Driven T Cell Expansion and Survival

(2014) J. Song et al.   JOURNAL OF IMMUNOLOGY

Targeting the Effector Site with IFN-  -Inducing TLR Ligands Reactivates Tumor-Resident CD8 T Cell Responses to Eradicate Established Solid Tumors

(2014) A. J. Currie et al.   JOURNAL OF IMMUNOLOGY

Targeting macrophages rescues age-related immune deficiencies in C57BL/6J geriatric mice

(2013) Connie Jackaman et al.   AGING CELL

Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy

(2013) Matthew D. Vesely et al.   Annals of the New York Academy of Sciences

Tumor-Associated Macrophages as a Paradigm of Macrophage Plasticity, Diversity, and Polarization

(2013) Alberto Mantovani et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Myeloid-Derived Suppressor Cells as a Vehicle for Tumor-Specific Oncolytic Viral Therapy

(2013) S. Eisenstein et al.   CANCER RESEARCH

Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors

(2013) J. Duraiswamy et al.   CANCER RESEARCH

Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination

(2013) I. Melero et al.   CLINICAL CANCER RESEARCH

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

(2013) Aurélien Marabelle et al.   JOURNAL OF CLINICAL INVESTIGATION

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Local Administration of TLR Ligands Rescues the Function of Tumor-Infiltrating CD8 T Cells and Enhances the Antitumor Effect of Lentivector Immunization

(2013) H. Xiao et al.   JOURNAL OF IMMUNOLOGY

Inhibition of p300 impairs Foxp3+ T regulatory cell function and promotes antitumor immunity

(2013) Yujie Liu et al.   NATURE MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC)

(2012) Suzanne Ostrand-Rosenberg et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell-Based Vaccination in Metastatic Melanoma

(2012) E. H. J. G. Aarntzen et al.   CANCER RESEARCH

MSCs, Macrophages, and Cancer: A Dangerous Ménage-à-Trois

(2012) Alberto Mantovani   Cell Stem Cell

Programmed Death Ligand 2 in Cancer-Induced Immune Suppression

(2012) Esdy N. Rozali et al.   Clinical & Developmental Immunology

Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma

(2012) Scott M. Schuetze et al.   EUROPEAN JOURNAL OF CANCER

IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase

(2012) Connie Jackaman et al.   INTERNATIONAL IMMUNOLOGY

Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer

(2012) Yung-Chang Lin et al.   INTERNATIONAL JOURNAL OF CANCER

Augmented Macrophage Differentiation and Polarization of Tumor-associated Macrophages Towards M1 Subtype in Listeria-administered Tumor-bearing Host

(2012) Rakesh K. Rai et al.   JOURNAL OF IMMUNOTHERAPY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dual Anti-OX40/IL-2 Therapy Augments Tumor Immunotherapy via IL-2R-Mediated Regulation of OX40 Expression

(2012) William L. Redmond et al.   PLoS One

Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression

(2012) Suzanne Ostrand-Rosenberg et al.   SEMINARS IN CANCER BIOLOGY

Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155

(2012) Xing Cai et al.   Journal of Molecular Cell Biology

The Inflammatory Microenvironment in Hepatocellular Carcinoma: A Pivotal Role for Tumor-Associated Macrophages

(2012) Daria Capece et al.   Biomed Research International

Turning the tumor microenvironment into a self vaccine site

(2012) Delia J. Nelson   OncoImmunology

Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation

(2012) Alison M. McDonnell et al.   OncoImmunology

Intratumoral interleukin-2/agonist CD40 antibody drives CD4+-independent resolution of treated-tumors and CD4+-dependent systemic and memory responses

(2011) Connie Jackaman et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Targeted Therapeutic Remodeling of the Tumor Microenvironment Improves an HER-2 DNA Vaccine and Prevents Recurrence in a Murine Breast Cancer Model

(2011) D. Liao et al.   CANCER RESEARCH

Early Detection of Tumor Cells by Innate Immune Cells Leads to Treg Recruitment through CCL22 Production by Tumor Cells

(2011) J. Faget et al.   CANCER RESEARCH

Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: A single-arm phase II study

(2011) Renee Vermeij et al.   INTERNATIONAL JOURNAL OF CANCER

Targeted drug delivery to tumors: Myths, reality and possibility

(2011) You Han Bae et al.   JOURNAL OF CONTROLLED RELEASE

Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

(2011) O. S. Qureshi et al.   SCIENCE

Cytokine-armed vaccinia virus infects the mesothelioma tumor microenvironment to overcome immune tolerance and mediate tumor resolution

(2010) C Jackaman et al.   CANCER GENE THERAPY

Selective Depletion of Foxp3+ Regulatory T Cells Improves Effective Therapeutic Vaccination against Established Melanoma

(2010) K. Klages et al.   CANCER RESEARCH

Conditional Regulatory T-Cell Depletion Releases Adaptive Immunity Preventing Carcinogenesis and Suppressing Established Tumor Growth

(2010) M. W. L. Teng et al.   CANCER RESEARCH

Tumor Antigen Cross-Presentation and the Dendritic Cell: Where it All Begins?

(2010) Alison M. McDonnell et al.   Clinical & Developmental Immunology

Nanoparticles for Tumor Targeted Therapies and Their Pharmacokinetics

(2010) Jianqiu Wang et al.   CURRENT DRUG METABOLISM

CD8α+ DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor

(2010) Alison M. McDonnell et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

CD40-activated B cells contribute to mesothelioma tumor regression

(2010) Connie Jackaman et al.   IMMUNOLOGY AND CELL BIOLOGY

Elevated frequencies of CD4+CD25+CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia

(2010) Zhang Shenghui et al.   INTERNATIONAL JOURNAL OF CANCER

Adjuvant Therapy With Agonistic Antibodies to CD134 (OX40) Increases Local Control After Surgical or Radiation Therapy of Cancer in Mice

(2010) Michael J. Gough et al.   JOURNAL OF IMMUNOTHERAPY

Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation

(2010) Adam D. Cohen et al.   PLoS One

The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications

(2010) Anna Maria Di Giacomo et al.   SEMINARS IN ONCOLOGY

Correlation of CXCL12 Expression and FoxP3 + Cell Infiltration with Human Papillomavirus Infection and Clinicopathological Progression of Cervical Cancer

(2009) Fatimah Jaafar et al.   AMERICAN JOURNAL OF PATHOLOGY

Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells

(2009) C. Jackaman et al.   EUROPEAN RESPIRATORY JOURNAL

OX40 costimulation can abrogate Foxp3+regulatory T cell-mediated suppression of antitumor immunity

(2009) Naomi Kitamura et al.   INTERNATIONAL JOURNAL OF CANCER

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis

(2009) Daniel Hirschhorn-Cymerman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

(2009) Karl S. Peggs et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy

(2009) S. A. Broomfield et al.   JOURNAL OF IMMUNOLOGY

DIRECT INTRATUMORAL CHEMOTHERAPY WITH CARBOPLATIN AND EPINEPHRINE IN A RECURRENT CERVICAL CHORDOMA

(2009) Séverine Guiu et al.   NEUROSURGERY

Cancer Immunotherapy by Dendritic Cells

(2008) Cornelis J.M. Melief   IMMUNITY

Deliberately provoking local inflammation drives tumors to become their own protective vaccine site

(2008) Connie Jackaman et al.   INTERNATIONAL IMMUNOLOGY

Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice

(2008) Juliana Hamzah et al.   JOURNAL OF CLINICAL INVESTIGATION

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

(2008) Silvia Piconese et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Hypoxia Enhances Tumor Stemness by Increasing the Invasive and Tumorigenic Side Population Fraction

(2008) Bikul Das et al.   STEM CELLS